Abstract
In order to estimate consensus in typing and grading of oligodendroglial tumors (OD) and to correlate the consensus diagnosis with 1p/19q status and response to treatment, we performed a panel review (9 neuropathologists) of 114 patients included in EORTC trial 26951 (temozolomide / radiotherapy in AOD). The original diagnosis of AOD made in 90 (of 114) cases by the local pathologists (79%) was confirmed in 33% to 68% of cases (mean: 55%). The diagnosis of AOA made in 24 (of 114) cases by the local pathologists (21%) was confirmed in 7% to 34% (mean: 19%). Consensus on the diagnosis of AOD was reached in 84% of cases with high concordance (ICC 86%). The concordance was independent of the 1p/19q status. The survival curves for (consensus) OD, AOD, AOA and GBM ran separately in this consecutive order (AOA and GBM intertwined). The Kaplan-Meyer curves for tumor grade, irrespective of tumor type, ran in the expected order and were significantly different from each other. Further, highest concordance was found for necrosis (ICC 92%) followed by endothelial abnormalities (ICC 87%), cell density (ICC 85%) and mitotic activity (ICC 85%). The absence of necrosis, the presence of endothelial proliferation and low cell density are correlated with better outcomes. In multivariate analysis, age and necrosis appeared to be independent prognostic factors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
